Market LIVE
Published markets; coverage varies by country
Product profile · United States

ZYNRELEF KIT

 ·  Patent Litigation & Settlement History ↓

IngredientBUPIVACAINE; MELOXICAM
Application typeNDA
Application211988
Product004
Dosage formSOLUTION, EXTENDED RELEASE
RoutePERIARTICULAR
Strength400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML)
Approval date2021-05-12
Marketing statusPrescription
Status event—
ApplicantHERON THERAPS INC
Product source

Current GenericRadar decision

Year2035
SelectionDEEP_REVIEW
ReviewFINAL_CHECKING
Anchor typeDS_EQUIVALENT
Anchor date2035-04-20
Patent anchor2035-04-20
Exclusivity anchor2024-05-12
Protection date—
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2035. Anchor type: DS_EQUIVALENT. Patent anchor: 2035-04-20. Exclusivity anchor: 2024-05-12. Anchor date: 2035-04-20. Patent tail: yes. Exclusivity tail: no. Review status: FINAL_CHECKING. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
103986862034-03-13DP ————
———
112535042034-03-13U U-3118———
———
95922272034-03-13DP/U U-3118———
———
97441632034-03-13DP ————
———
99139092034-03-13U U-3118———
———
100989572035-04-20U U-3118———
———
102135102035-04-20DP/U U-3118———
———
106321992035-04-20DP/U U-3118———
———
108985752035-04-20DP/U U-3118———
———
109808862035-04-20DP ————
———
110837302035-04-20DP/U U-3118———
———
110837972035-04-20DP/U U-3118———
———
114133502035-04-20U U-3417———
———
96940792035-04-20DP/U U-3118———
———
98019452035-04-20DP/U U-3118———
———
118448372036-04-21U U-3417———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
I-933—2027-01-23————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.